The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across the globe, including in areas where the PURPOSE trials were conducted.

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

FDA approves Yeztugo HIV prevention injection showing 96% efficacy in clinical trials, but $14,000 cost creates significant access barriers for patients.

In two recent studies, this new shot reportedly nearly eliminated new infections in people at substantial risk of HIV.

Dozens of HIV experts at the Centers for Disease Control and Prevention received emails earlier in June revoking notices they ...

The U.S. Food and Drug Administration has approved a groundbreaking new HIV prevention drug that offers near-total protection with just two injections per year. Sold under the name Yeztugo, the shot ...

Kathy Seward MacKay lost her husband in 1997 because of tainted blood-clotting products. She’s worried about history ...

The US FDA has approved lenacapvir, sold under the brand name Yeztugo, as the first preventive treatment against HIV. It is a ...

WASHINGTON (AP) — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated ...

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...

A new twice-yearly shot could be a "game changer" in the fight against AIDS, but experts' hopes have dimmed because of the ...